The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2016 | How pembrolizumab will change the management of advanced lung cancer
Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany discusses the implication of the KEYNOTE-024 trial results for advanced lung cancer. According to Dr Reck, this data will completely change the management of patients. At diagnosis, we have to look at oncogenic alterations but now it is also important to screen patients for PD-L1 expression. Patients with high PD-L1 can be treated with pembrolizumab, which is now an option for first-line therapy for this group of patients.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
